Anti‐adiposity and lipid‐lowering effects of schisandrol A in diet‐induced obese mice

Abstract

Lignan schisandrol A (SolA) is known to have antioxidant and anti‐inflammatory effects. However, the impact of SolA on obesity is poorly understood. To test the hypothesis that SolA has anti‐obesity effects, C57BL/6J mice were fed a high‐fat diet with or without SolA (0.006%, w/w) for 16 weeks. SolA decreased visceral fat mass (10%) by increasing energy expenditure and upregulating white adipose tissue thermogenic genes mRNA expression. Furthermore, SolA upregulated adipose Lpl mRNA expression and decreased plasma free fatty acid (FFA), triglyceride (TG), apolipoprotein (apo) B, aspartate aminotransferase levels and TG/HDL‐cholesterol and apoB/apoA1 ratios as well as hepatic lipid droplets. Increased hepatic β‐oxidation and fecal FFA and TG levels were observed in the SolA‐supplemented mice, suggesting an association of its lipid‐lowering effect with increased hepatic β‐oxidation, fecal fat excretion and adipose Lpl. Conclusionally, this study provides evidence on the protective effects of SolA against adiposity, dyslipidemia and nonalcoholic fatty liver disease in obese mice.